ABCL Share Price Performance
US$4.05
1.45 (55.77%)
58.8% undervalued intrinsic discount
US$9.83
Fair Value
Price US$4.05
AnalystConsensusTarget US$9.83
AnalystLowTarget US$7.00
AnalystHighTarget US$12.00
Fair ValueUS$9.83
Share Pricen/a
AbCellera Biologics Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 99 Fair Values set on narratives written by author
ABCL Community Narratives
AN
Fair Value
·Fair Value US$9.83 58.8% undervalued intrinsic discount
Phase I Trials And Manufacturing Will Unlock Pipeline Potential
0users have liked this narrative
0users have commented on this narrative
51users have followed this narrative
AN
Fair Value
·Fair Value US$7 42.1% undervalued intrinsic discount
Clinical And Regulatory Risks Will Limit Upside Despite Potential Recovery
0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AN
Fair Value
·Fair Value US$12 66.3% undervalued intrinsic discount
AI Integration And Internal Pipeline Will Accelerate Biologics Growth
1users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
Clinical And Regulatory Risks Will Limit Upside Despite Potential Recovery
Key Takeaways Heavy investment in proprietary technology positions AbCellera for growth, but dependence on clinical milestones and royalties exposes it to significant revenue volatility. Intensified competition, regulatory scrutiny, and alternative therapies may constrain future market share and earnings despite favorable industry trends.Read more
AN
US$7
42.1% undervalued intrinsic discount
Fair Value
Profit Margin
15.46%
Future PE
422.65x
Price in 2029
US$8.76
AI Integration And Internal Pipeline Will Accelerate Biologics Growth
Key Takeaways Innovative trial execution, distinctive product features, and AI-driven antibody discovery position AbCellera to quickly gain market share and attract significant partner interest. Efficient R&D investment, advanced manufacturing, and growing internal pipeline set the stage for improved profitability and outsized long-term royalty and milestone revenues.Read more
AN
US$12
66.3% undervalued intrinsic discount
Fair Value
Profit Margin
15.51%
Future PE
383.58x
Price in 2029
US$15.01
Phase I Trials And Manufacturing Will Unlock Pipeline Potential
Key Takeaways Transition to a clinical-stage biotech and internal programs could drive revenue through milestone fees and royalty payments from new molecules. Integrated clinical manufacturing capabilities will likely boost efficiency and margins, while strong liquidity supports long-term pipeline development.Read more
AN
US$9.83
58.8% undervalued intrinsic discount
Fair Value
Profit Margin
15.74%
Future PE
187.27x
Price in 2029
US$12.29
Trending Discussion
Recently Updated Narratives
AN
ABCL: Platform And Partnerships Will Support Future Upside Potential
Fair Value: US$7 42.1% undervalued intrinsic discount
7 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ABCL: Patent Settlement And Menopause Trial Will Support A Stronger Outlook
Fair Value: US$12 66.3% undervalued intrinsic discount
6 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ABCL: Menopause Phase 2 Progress And Bruker Settlement Will Support Future Margins
Fair Value: US$9.83 58.8% undervalued intrinsic discount
51 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
AbCellera Biologics Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
May 11, 2026
- -0.48
- -148.68%
- -194.88%
- 0%
About ABCL
- Founded
- 2012
- Employees
- 562
- CEO
- WebsiteView website
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
